What changed in this filing

/stocks — the workspaceLOADING

Item 2. Unregistered Sales of Equity Securities

2018-11-13 compared with 2018-08-08 · 26 added, 24 removed, 42 unchanged (54% of the section changed)

1 unchanged sentence

Proceeds from Registered Securities

On October 30, 2017, the Company consummated its

initial public offering of 18,000,000 units.

On October 30, 2017, the Company consummated

its initial public offering of 18,000,000 units.

The Units were sold at an offering price of $10.00 per Unit, generating gross

proceeds of $180,000,000.

Simultaneously with the closing of the IPO, the Company consummated a private placement with Shareholder Value Fund, our sponsor, of 475,000 units at a price of $10.00 per Private Unit, generating total proceeds of $4,750,000.

Subsequently, the underwriters exercised the over-allotment

option in part and, on November 3, 2017, the underwriters purchased 2,636,293 over-allotment option Units, which were sold at an

offering price of $10.00 per Unit, generating gross proceeds of $26,362,930.

On November 3, 2017, simultaneously with the sale

of the over-allotment units, the Company consummated the private sale of an additional 52,726 Private Units, generating gross proceeds

On November 3, 2017, the underwriters canceled the remainder of the over-allotment option.

In connection with the

cancellation of the remainder of the over-allotment option, the Company canceled an aggregate of 15,927 ordinary shares issued

to Shareholder Value Fund, the Company’s sponsor, prior to the IPO and Private Placement.

As of November 3, 2017, a total of $ 206,362,930 of the net proceeds from the sale of the Units in the IPO (including the over-allotment) and the Private Placements were in a trust account established for the benefit of the Company’s public shareholders.

The Private Units are identical to the Units sold

in the IPO except that the warrants included in the Price Units will be non-redeemable and may be exercised on a cashless basis,

in each case so long as they continue to be held by our Sponsor or its permitted transferees.

Additionally, because the Private

Units were issued in a private transaction, our Sponsor and its permitted transferees will be allowed to exercise the warrants

Simultaneously with the closing of the IPO, the Company consummated a private placement with Shareholder

Value Fund, our sponsor, of 475,000 units at a price of $10.00 per Private Unit, generating total proceeds of $4,750,000.

Subsequently,

the underwriters exercised the over-allotment option in part and, on November 3, 2017, the underwriters purchased 2,636,293 over-allotment

option Units, which were sold at an offering price of $10.00 per Unit, generating gross proceeds of $26,362,930.

On November 3,

2017, simultaneously with the sale of the over-allotment units, the Company consummated the private sale of an additional 52,726

Private Units, generating gross proceeds of $527,260.

On November 3, 2017, the underwriters canceled the remainder of the over-allotment

In connection with the cancellation of the remainder of the over-allotment option, the Company canceled an aggregate of

15,927 ordinary shares issued to Shareholder Value Fund, the Company’s sponsor, prior to the IPO and Private Placement.

of November 3, 2017, a total of $ 206,362,930 of the net proceeds from the sale of the Units in the IPO (including the over-allotment)

and the Private Placements were in a trust account established for the benefit of the Company’s public shareholders.

The Private Units are identical to the

Units sold in the IPO except that the warrants included in the Price Units will be non-redeemable and may be exercised on a cashless

basis, in each case so long as they continue to be held by our Sponsor or its permitted transferees.

Additionally, because the

Private Units were issued in a private transaction, our Sponsor and its permitted transferees will be allowed to exercise the warrants

included in the Private Units for cash even if a registration statement covering the Ordinary Shares issuable upon exercise of

17 unchanged sentences

business combination.

We paid a total of $4,127,259 in underwriting discounts

and commissions and

$881,326 for other costs and expenses related to the IPO.

For a description of the use of the proceeds generated

in our IPO, see Part I, Item 2 of this Form 10-Q.

We paid a total of $4,127,259 in underwriting

discounts and commissions and $881,326 for other costs and expenses related to the IPO.

For a description of the use of the proceeds

generated in our IPO, see Part I, Item 2 of this Form 10-Q.

Share Exchange Agreement dated November 2, 2018 (incorporated by reference to Exhibit 2.1 of the registrant’s Current Report on Form 8-K filed with the SEC on November 6, 2018)

Certification of Chief Executive Officer pursuant to Rule 13a-14 and Rule 15d-14(a), promulgated under the Securities and Exchange Act of 1934, as amended.

17 unchanged sentences

(Principal financial and accounting officer)

August 8, 2018

November 13, 2018

Compared sentence by sentence after normalising whitespace, quotation marks, case and digits, so re-formatting and restated figures do not read as changed language. Wording changes appear as one removal and one addition. The current filing and the prior one are authoritative.

What changed 10-Q

Item 2. Unregistered Sales of Equity Securities